Receipt date: 12/20/2006

12-22-05

+

10533144 - GAU 6554

Please type a plus sign (+) inside this box →

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Q.E.		RIPE	Application Number	10/533,144		
- "	WALL AND ALL THE ALL T	**	Filing Date	April 24, 2006		
EL 2 4 7	TRANSMITTAL FORM	DEC 2 0 2006	First Named Inventor	MASUDA, ESTEBAN		
EC 2	FORM Y		Group Art Unit	1654		
Water N	(100 be used for all correspondence after ini	tial filing ADEMARK	Examiner Name	Not yet assigned		
	Total Number of Pages in This Submissi	22	Attorney Docket Number	RIGL-023		
	Total Hallbor of Fagge III Will Cooking		ES (check all that apply)			
	Fee Transmittal Form		ment Papers Application)	After Allowance Communication to Group		
	Fee Attached	Drawir Drawir	ng(s)	Appeal Communication to Board of Appeals and Interferences		
	Amendment / Reply After Final Affidavits/declaration(s)	Licens Petitio	ing-related Papers n	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
	Extension of Time Request Express Abandonment Request	Provisional A Power of Atto Change of C Address	n to Convert to a ional Application of Attorney, Revocation	Proprietary Information Status Letter		
	Supplemental Information Disclosure Statement			Other Enclosure(s) (please identify below): Form PTO/SB/08A 3 references:		
	Certified Copy of Priority Documents	Reque	st for Refund	Kinsella et al. Nutt et al.		
	Response to Missing Parts/ Incomplete Application	CD, N	umber of CD(s	Craik et al. Supplementary European Search Report Return postcard		
	Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks				
	SIGNA	TURE OF APPL	ICANT, ATTORNEY, OR	AGENT		
Signing Attorney/Agent (Reg. No.) JAMES S. KEDDIE, PH.D., 48,920 BOZ CEVIC, FIELD & FRANCIS, LLP						
Date December 20, 2006						
EXPRESS MAIL LABEL NO. EV 687 640 743 US						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Receipt date: 12/20/2006 10533144 - GAU: 1654

Express Mail No. EV 687 640 743 US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e)

DEC 2 0 2006

Address to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attorney Docket	RIGL-023	
First Named Inventor	MASUDA, ESTEBAN	
Application Number	10/533,144	
Confirmation No.	5373	
Filing Date	April 24, 2006	
Group Art Unit	1654	
Examiner Name	Not yet assigned	

Title: "METHODS OF SCREENING CYCLIC PEPTIDES AND IDENTIFYING TARGETS THEREFOR"

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. RIGL-023.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

James S. Keddie, Ph.D., Reg. No. 48,920

Date: December 20, 2006

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

Please type a plus sign (+) inside this box \rightarrow

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/533,144	
	SUPPLEMEI	NTAL		Filing Date	April 24, 2006	
	INFORMATION DIS	SCLOSUF	RE	First Named Inventor	MASUDA, Esteban	
STATEMENT BY APPLICANT			IT	Group Art Unit	1654	
				Examiner Name	TO BE ASSIGNED	
(use as many sheets as necessary)						
108 heet	1	of	1	Attorney Docket Number	RIGL-023	

U.S. PATENT DOCUMENTS Pages, columns, lines, U.S. Patent Documents Cite Name of Patentee or Applicant **Date of Publication** Examin Where Relevant No.1 Kind Code² of Cited Documents of Cited Document Number Passages or Relevant MM-DD-YYYY Initials' (if known) Figures Appear

	FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No. ¹	Foreign Patent Documents		ocuments	Name of Patentee or	Date of Publication	Pages, Columns, Lines, Where Relevant		
		Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
/C.B./		KINSELLA et al., "Retrovirally Delivered Random Cyclic Peptide Libraries Yield Inhibitors of Interleukin-4 Signaling in Human B Cells", J of Bio Chem, Vol. 277, No. 40 (Oct. 2002), pp 37512-37518.				
		NUTT et al., "Preparation of peptides having atrial natriuretic factor activity identification of a region in alcohol dehydrogenase that binds to .alphacrystallin during chaperone action Recombinant production of proteins in transformed bacteria using chaperonin				
		GroEL, and the chaperonin binding domain", Merck and Co., Inc., USA, (January 1992)				
		CRAIK et al., "Genes encoding insecticidal cystine-knotted macrocyclic proteins of plants and their uses". The University of Queensland, Australia: Latrobe University (May				
		2001)				
			<u> </u>			

Examiner	/Christina Bradley/	Date
Signature		Considered

Burden hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.